Ginsenoside Rg3 (Shenyi Capsule)‎ Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

المؤلفون المشاركون

Zhang, Tingting
Pan, Lin-Lin
Liu, Gui-Rong
Sun, Haiyang

المصدر

Evidence-Based Complementary and Alternative Medicine

العدد

المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-19، 19ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2019-12-17

دولة النشر

مصر

عدد الصفحات

19

التخصصات الرئيسية

الطب البشري

الملخص EN

Objective.

In China, ginsenoside Rg3 is often used in combination with chemotherapy to treat digestive system cancer.

We here performed a meta-analysis and systematic review to provide a much needed high-quality evaluation of the efficacy and safety of ginsenoside Rg3 combined with chemotherapy in these cancers.

Materials and Methods.

The PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu (VIP) databases were searched.

All randomized controlled trials (RCTs) concerning ginsenoside Rg3 combined with chemotherapy for digestive system cancer were selected.

Dichotomous data were expressed as odds ratios (ORs) with 95% confidence intervals (CI).

The methodological quality of the included studies was evaluated according to the Cochrane evidence-based medicine system, and the statistical analyses were performed with Review Manager 5.3 and STATA 12.0 software.

In addition, the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of the evidence.

Trial sequential analysis (TSA) was used to evaluate information size and treatment benefits.

Results.

A total of 18 trials comprising 1531 patients were included in this study.

The results revealed that the trials were of sufficient standard to draw reliable conclusions that ginsenoside Rg3 combined with chemotherapy could improve the objective response rate (ORR; OR 2.17, 95% CI 1.72–2.73), disease control rate (DCR; OR 2.83, 95% CI 2.02–3.96), 1-year survival rate (SR; OR = 2.33, 95% CI = 1.24–4.37), Karnofsky Performance Scale (KPS; OR 2.67, 95% CI 1.76–4.03), gastrointestinal dysfunction (OR 0.44, 95% CI 0.31–0.61), and the decline of leucocyte count (OR 0.28, 95% CI 0.21–0.38).

Conclusion.

Ginsenoside Rg3 combined with chemotherapy can improve the clinical efficacy and alleviate treatment-induced side effects for digestive system cancer.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Pan, Lin-Lin& Zhang, Tingting& Sun, Haiyang& Liu, Gui-Rong. 2019. Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-19.
https://search.emarefa.net/detail/BIM-1148938

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Pan, Lin-Lin…[et al.]. Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-19.
https://search.emarefa.net/detail/BIM-1148938

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Pan, Lin-Lin& Zhang, Tingting& Sun, Haiyang& Liu, Gui-Rong. Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-19.
https://search.emarefa.net/detail/BIM-1148938

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1148938